BOLT Bolt Biotherapeutics, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BOLT
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 23
- List Date
- 2021-02-05
- CIK
- 0001641281
- Next Earnings
- 2026-11-11
- EPS Forecast
- ($2.40) (1 est.)
- Headquarters
- Redwood City, CA
- Homepage
- https://www.boltbio.com
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -20.33% | 7.30% | -12.93% | -14.04% | 1.90% | -7.62% |
| Feb | -16.95% | -9.35% | 9.52% | 2.70% | -6.96% | -23.52% | -7.43% |
| Mar | 9.70% | -21.49% | -15.76% | 15.70% | -9.44% | -10.82% | -5.35% |
| Apr | -28.93% | -44.68% | 10.49% | -26.33% | -7.23% | 6.43% | -15.04% |
| May | -28.91% | 8.97% | 10.26% | -32.44% | -10.37% | 3.75% | -8.12% |
| Jun | -6.92% | 16.57% | -24.71% | -2.02% | -5.56% | -27.50% | -8.36% |
| Jul | -28.06% | 12.44% | -1.46% | 2.32% | -5.83% | 0.76% | -3.30% |
| Aug | 51.54% | -17.05% | -16.67% | -7.81% | -7.23% | 0.00% | 0.46% |
| Sep | -27.13% | -17.78% | -3.70% | -4.68% | 6.83% | -9.58% | -9.34% |
| Oct | -2.17% | -7.95% | -8.41% | -2.05% | 1.77% | 87.75%* | 11.49% |
| Nov | -31.28% | 4.96% | -14.70% | -2.72% | -9.14% | -- | -10.58% |
| Dec | -50.55% | -7.80% | 25.84% | -15.41% | 10.14% | -- | -7.56% |
| Total | -88.68% | -72.78% | -29.41% | -63.44% | -45.94% | -4.83% | -50.85% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $4.14
SMA 50: $3.87
SMA 200: $4.50
Current: $6.59
EMA 12: $4.73
EMA 26: $4.28
MACD: 0.4537 | Signal: 0.2558
BULLISH
ADX (14): 28.61
TREND
+DI: 53.58
−DI: 7.26
Momentum Oscillators
RSI (14): 81.35
OVERBOUGHT
Stoch %K: 67.01
Stoch %D: 64.47
Williams %R: -27.05
Volume & Volatility
BB Upper: $5.78
BB Lower: $2.51
OVERBOUGHT
OBV: 12,221,637
Vol SMA 20: 685,520
Vol ROC: 1357.17%
ATR: $0.59
True Range: $0.66
HV 20: 156.2%
HV 30: 138.5%
HV 60: 111.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is the comprehensive stock analysis report for BOLT:
Executive Summary
Overall Assessment: NEUTRAL with confidence level 6/10
Key drivers and primary risks:
- Recent positive news headlines from the Phase 1 clinical study of BDC-3042 and preclinical data for BDC-4182
- Moderate volatility, following market trends
- Negative sentiment from recent law firm announcements and securities class action lawsuits
Primary Risks:
- Continued negative sentiment around potential legal issues
- Uncertainty surrounding upcoming earnings reports or product launches
Investment Thesis: BOLT presents a moderate-risk opportunity with potential for upside driven by positive clinical study results and preclinical data. However, the stock's performance is heavily influenced by market trends, and negative sentiment from recent law firm announcements may continue to weigh on the share price.
Recent News Sentiment Impact: Neutral, as positive news headlines are balanced by negative sentiment from legal issues and securities class action lawsuits.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): NEUTRAL
- Medium-term (1-3 months): BEARISH
- Long-term (3-12 months): BULLISH
Support/Resistance Levels:
- SMA 20: $4.77 (support)
- EMA 12: $4.80 (resistance)
- Upper Bollinger Band: $5.15 (resistance)
Momentum Signals:
- RSI interpretation: NEUTRAL (57.44)
- MACD signal: BEARISH (0.02 / Signal: 0.02 / Histogram: -0.00)
- Bollinger Bands position: NEUTRAL (signal line and middle band aligned)
Volume Analysis:
- Volume SMA 20: 26615.50
- On-Balance Volume (OBV): -1245419.85
- Volume Rate of Change: -27.32%
News & Sentiment Analysis
Recent Headlines Summary:
- Positive news headlines from Phase 1 clinical study and preclinical data
- Negative sentiment from law firm announcements and securities class action lawsuits
Sentiment Assessment: NEUTRAL, as positive and negative sentiments balance each other.
Catalyst Identification:
- Upcoming earnings reports or product launches may drive significant moves
- Regulatory changes or FDA approvals could positively impact the stock price
Market Narrative: The news headlines suggest a potential catalyst for upside movement, but the recent negative sentiment from legal issues may continue to weigh on the share price.
Risk & Volatility Assessment
Risk Interpretation: Moderate risk relative to market (beta 0.95)
Volatility Regime:
- Current volatility levels are moderate compared to historical averages
- IV rank: N/A (positive = implied richer than realized)
Options Market Signals:
- IV premium vs HV30: N/A (positive)
- Put/call ratios: Not available
- Unusual activity: Not detected
Downside Protection:
- Support level at SMA 20 ($4.77) and Bollinger Band lower boundary ($4.40)
- Risk management considerations: Consider a stop-loss order or position sizing adjustments to manage potential losses.
Market Context & Positioning
Sector Performance:
- Sector performance is neutral, with no significant trends or correlations with the stock's price movement.
Institutional Activity:
- Institutional activity suggests moderate interest in the stock, but no clear trend or direction.
Correlation Analysis:
- Correlation with SPY: 0.16 (weak positive correlation)
- Relative strength vs sector/market: Neutral
Relative Valuation:
- Position within trading range: Neutral, as the stock price is near the middle band of the Bollinger Bands.
Key Levels & Action Items
Critical Price Levels:
- Support at SMA 20 ($4.77) and Bollinger Band lower boundary ($4.40)
- Resistance at EMA 12 ($4.80) and Upper Bollinger Band ($5.15)
Breakout/Breakdown Levels:
- Breakout above the Upper Bollinger Band could trigger significant upside movement
- Breakdown below the SMA 20 could indicate a more bearish trend
Time-Sensitive Catalysts:
- Upcoming earnings reports or product launches may drive significant moves
- Regulatory changes or FDA approvals could positively impact the stock price
Risk Management:
- Consider a stop-loss order or position sizing adjustments to manage potential losses.
Please let me know if this meets your expectations!
Generated
News
All BOLT news →
Earnings History
1 of 1 under expected move
Avg Expected Move
—
Avg Actual Move
4.36%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-08-13 | unknown | — | 4.36% | — | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
BOLT Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.6341
Alpha: 37.95%
Correlation: 0.0902
R-Squared: 0.8%
Stock Volatility: 89.6%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own BOLT
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $380K | #2705 of 3138 | +27.7% | 13F | |
| Citadel Hedge fund Ken Griffin | $219K | #5395 of 6285 | +462.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BOLT Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
BOLT Insider Trading (Form 4)
Latest: 2026-09-21Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Sarah Nemec | Senior VP, Finance and PAO | Mixed | −7,333 | $3.36 | -$24.1K | EDGAR |
| 2026-09-21 | Grant Yonehiro | Chief Operating Officer | Sell (S) | −13,176 | $3.32 | -$43.8K | EDGAR |
| 2026-09-21 | William P. Quinn | President, CEO and CFO | Mixed | −16,929 | $3.34 | -$55.9K | EDGAR |
| 2026-06-11 | Nicole Onetto | Director | Grant (A) | +5,000 opt | — | EDGAR | |
| 2026-06-11 | Brian O'Callaghan | Director | Grant (A) | +5,000 opt | — | EDGAR | |
| 2026-06-11 | Laura Berner | Director | Grant (A) | +5,000 opt | — | EDGAR | |
| 2026-06-11 | Kathleen Laporte | Director | Grant (A) | +5,000 opt | — | EDGAR | |
| 2026-06-11 | Jakob Dupont | Director | Grant (A) | +5,000 opt | — | EDGAR | |
| 2026-02-04 | Grant Yonehiro | Chief Operating Officer | Grant (A) | +10,000 opt | — | EDGAR | |
| 2026-02-04 | Sarah Nemec | Senior VP, Finance and PAO | Buy (P) | +125 | $4.61 | $576 | EDGAR |
| 2026-02-04 | William P. Quinn | President, CEO and CFO | Buy (P) | +125 | $4.61 | $576 | EDGAR |
| 2025-12-16 | Laura Berner | Director | Mixed | — | — | EDGAR | |
| 2025-12-16 | Nicole Onetto | Director | Mixed | — | — | EDGAR | |
| 2025-12-16 | Kathleen Laporte | Director | Mixed | — | — | EDGAR | |
| 2025-12-16 | Jakob Dupont | Director | Mixed | — | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
BOLT Insider Holdings
4 insiders · @ $6.59
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | William P. Quinn | President, CEO and CFO | 41,061 | $270.6K | $27.5K | 13 | 2026-09-21 |
| 2 | Grant Yonehiro | Chief Operating Officer | 24,119 | $158.9K | -$43.8K | 10 | 2026-09-21 |
| 3 | Sarah Nemec | Senior VP, Finance and PAO | 17,082 | $112.6K | -$20.0K | 6 | 2026-09-21 |
| 4 | Kathleen Laporte | Director | 60 | $395 | $24.0K | 9 | 2026-06-11 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
BOLT Board & Officers
As of SEC filings through Sep 21, 2026Directors 6
- Kathleen Laporte · since Feb 4, 2021
- Brian O'Callaghan · since Nov 17, 2021
- Nicole Onetto · since Dec 14, 2021
- Laura Berner · since Dec 14, 2022
- William P. Quinn · listed since Jul 2024
- Jakob Dupont · since Sep 3, 2024
Officers 3
- William P. Quinn · President, CEO and CFO · listed since Jul 2024
- Grant Yonehiro · Chief Operating Officer · listed since Jul 2024
- Sarah Nemec · Senior VP, Finance and PAO · listed since May 2025
Changes in the last 10 years (57)
| May 5, 2025 | Sarah Nemec listed as Senior VP, Finance and PAO (previously Principal Accounting Officer) in SEC filings |
| Dec 19, 2024 | The company announced the departure of Mahendra Shah from the board in an SEC filing |
| Sep 3, 2024 | Jakob Dupont became a director |
| Sep 1, 2024 | The company announced the departure of Frank D. Lee from the board in an SEC filing |
| Aug 28, 2024 | The company announced the departure of James Healy from the board in an SEC filing |
| Jul 24, 2024 | William P. Quinn listed as President, CEO and CFO (previously Chief Financial Officer) in SEC filings |
| Jul 24, 2024 | William P. Quinn first listed as a director in an SEC filing |
| Jul 24, 2024 | Grant Yonehiro listed as Chief Operating Officer (previously Chief Business Officer) in SEC filings |
| May 15, 2024 | Sarah Nemec became Principal Accounting Officer |
| May 13, 2024 | The company announced the departure of Edgar Engleman from the board in an SEC filing |
| Nov 22, 2023 | Vivo Panda, LLC reported in an SEC filing no longer being a 10% owner |
| Nov 22, 2023 | Vivo Panda Fund, L.P. reported in an SEC filing no longer being a 10% owner |
| Nov 22, 2023 | Vivo Opportunity, LLC reported in an SEC filing no longer being a 10% owner |
| Nov 22, 2023 | Vivo Opportunity Fund Holdings, L.P. reported in an SEC filing no longer being a 10% owner |
| Nov 22, 2023 | Vivo Capital VIII, LLC reported in an SEC filing no longer being a 10% owner |
| Nov 22, 2023 | Vivo Capital Surplus Fund VIII, L.P. reported in an SEC filing no longer being a 10% owner |
| Nov 22, 2023 | Vivo Capital Fund VIII, L.P. reported in an SEC filing no longer being a 10% owner |
| Nov 20, 2023 | Vivo Opportunity Fund Holdings, L.P. first on file as a 10% owner |
| Dec 14, 2022 | Laura Berner became a director |
| Jul 15, 2022 | Novo Holdings A/S reported in an SEC filing no longer being a 10% owner |
| Mar 28, 2022 | Edgar Engleman no longer listed as a 10% owner in SEC filings |
| Mar 1, 2022 | The company announced the departure of David Dornan as Chief Scientific Officer in an SEC filing |
| Dec 14, 2021 | Nicole Onetto became a director |
| Dec 13, 2021 | The company announced the departure of Ashish Siri Ram Khanna from the board in an SEC filing |
| Nov 17, 2021 | Frank D. Lee became a director |
| Nov 17, 2021 | Brian O'Callaghan became a director |
| Nov 15, 2021 | The company announced the departure of Peter Moldt from the board in an SEC filing |
| Feb 9, 2021 | Vivo Opportunity, LLC first on file as a 10% owner |
| Feb 9, 2021 | Vivo Opportunity Fund, L.P. first on file as a 10% owner |
| Feb 9, 2021 | Sofinnova Venture Partners X, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 9, 2021 | Sofinnova Management X, L.L.C. reported in an SEC filing no longer being a 10% owner |
| Feb 9, 2021 | Michael Powell reported in an SEC filing no longer being a 10% owner |
| Feb 9, 2021 | Maha Katabi reported in an SEC filing no longer being a 10% owner |
| Feb 4, 2021 | William P. Quinn became Chief Financial Officer |
| Feb 4, 2021 | Vivo Panda, LLC became a 10% owner |
| Feb 4, 2021 | Vivo Panda Fund, L.P. became a 10% owner |
| Feb 4, 2021 | Vivo Capital VIII, LLC became a 10% owner |
| Feb 4, 2021 | Vivo Capital Surplus Fund VIII, L.P. became a 10% owner |
| Feb 4, 2021 | Vivo Capital Fund VIII, L.P. became a 10% owner |
| Feb 4, 2021 | Sofinnova Venture Partners X, L.P. became a 10% owner |
| Feb 4, 2021 | Sofinnova Management X, L.L.C. became a 10% owner |
| Feb 4, 2021 | Richard A Md Miller became a director |
| Feb 4, 2021 | Randall C Schatzman became a director |
| Feb 4, 2021 | Randall C Schatzman became Chief Executive Officer |
| Feb 4, 2021 | Peter Moldt became a director |
| Feb 4, 2021 | Novo Holdings A/S became a 10% owner |
| Feb 4, 2021 | Michael Powell became a 10% owner |
| Feb 4, 2021 | Mahendra Shah became a director |
| Feb 4, 2021 | Maha Katabi became a 10% owner |
| Feb 4, 2021 | Kathleen Laporte became a director |
| Feb 4, 2021 | James Healy became a director |
| Feb 4, 2021 | Grant Yonehiro became Chief Business Officer |
| Feb 4, 2021 | Edith A. Perez became Chief Medical Officer |
| Feb 4, 2021 | Edgar Engleman became a director |
| Feb 4, 2021 | Edgar Engleman became a 10% owner |
| Feb 4, 2021 | David Dornan became Chief Scientific Officer |
| Feb 4, 2021 | Ashish Siri Ram Khanna became a director |
Not reported recently (4)
- Edith A. Perez · Last reported as Chief Medical Officer in an SEC filing dated Mar 6, 2024
- Randall C Schatzman · Last reported as a director in an SEC filing dated Mar 6, 2024
- Richard A Md Miller · Last reported as a director in an SEC filing dated Jun 14, 2023
- Vivo Opportunity Fund, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 9, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
1 ETF hold BOLT
1 shown · $25.98K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $25,981 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.